March 28, 2026-- At ACC.26, Corcept Therapeutics Inc. presented late-breaking data from its MOMENTUM trial examining the prevalence of endogenous hypercortisolism in patients with resistant hypertension .
MOMENTUM screened 1,086 patients with resistant hypertension (as defined by the American Heart Association’s criteria) and found that 27.3 percent, or 297 patients had hypercortisolism. This finding complements the results of Corcept’s CATALYST trial, which found hypercortisolism in 23.8 percent of the 1,057 patients screened with difficult-to-control type 2 diabetes. The prevalence of hypercortisolism in patients who had hemoglobin A1c (HbA1c) of 7.5 percent or higher and were taking 3 or more blood pressure medicines was 32.6 percent in MOMENTUM and 36.6 percent in CATALYST.
“Resistant hypertension increases the risk of cardiovascular events like heart attacks, strokes, and heart failure, as well as kidney damage,” said Deepak L. Bhatt, M.D., M.P.H., M.B.A., Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai. “MOMENTUM shows that hypercortisolism contributes to resistant hypertension in over a quarter of patients and that screening for hypercortisolism in these challenging-to-treat patients may help physicians provide more personalized care.” Dr. Bhatt presented the data as Featured Clinical Research at ACC 2026, is a lead investigator and steering committee member for MOMENTUM, and a paid consultant to Corcept Therapeutics.
“It is now clear that hypercortisolism is more common than previously assumed in patients whose hypertension and diabetes don’t respond to standard-of-care treatments,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “We are grateful to the investigators and patients who have participated in this research and hope that the findings will provide critical information to support increased screening for hypercortisolism, more accurate diagnoses and improved treatment options.”
For more information, visit Corcept.com.
November 14, 2025 
